Clientele:
Biotechnology
Despite significant advances in science and technology, transforming a discovery into a marketed drug requires more time and money than ever before. Young, growing biotechnology firms who lack the revenue streams to support their investments need to attract repeated funding to keep afloat. More mature biopharmaceutical companies, who have products on the market or candidates approaching launch, must continually manage their pipeline without negatively impacting earnings. When novel products are launched into the market, they face intense competitive and pricing pressures that can threaten success.
We specialize in identifying and quantifying the commercial value for discoveries, product candidates, and marketed drugs. Our clientele ranges from 3 of the 5 most successful biotechnology companies to emerging players with promising pipelines. We have helped them build consensus around overall goals, cash requirements and product value. Our work has provided a systematic means of prioritizing research programs and product opportunities. It has also identified attractive acquisition targets to add capabilities or deepen existing product portfolios.
Living in a resource-constrained environment is a reality for biotechnology executives. To address commercialization needs, many seek relationships with pharmaceutical companies to outlicense, co-develop, or co-market their products. Our evaluations help management decide which products to outlicense and which rights to retain. If co-developing or co-marketing a product maximizes limited resources, Putnam's partnering due diligence and alliance management experience helps to identify and approach the best pharmaceutical match and clarifies performance and expectations for all parties involved.